Infusion Magazine

PHARMACY COMPOUNDING ISSUES

Baker Kenneth R. Sterile compounding oversight: Legal challenges, practice considerations.200713(2);20-3.

Bickley S. USP compliance: A journey. 2006. 12(5):32-6.

Chamallas SN, Fishwick J, Riesenberg M. Special delivery: Keeping the product stable during shipping. 1997;4(3):30-2.

Choy GS, Egging P, White B. Stability data for ambulatory infusion pump reservoirs. 1998;4(11):18-23.

Counce J. Digging deep: Infusion pharmacies bear the cost of USP <797> compliance. 2006:12(1):15-9.

Fagerman K. 4-Chamber total parenteral nutrition system: A "needleless" total nutrient admixture. 1997;3(12):15-9.

Ferris R. Pharmacoeconomics: Principals of balance. 1998;4(11):39-42.

Johnson K, Volkman G. Identifying and calculating activity-based pharmacy costs in home infusion and ambulatory care 1998;4(6):15-21.

Kastango ES and Bradshaw B. Sterile product compounding: Developing quality-based standards for pharmacy practice. 2003;9(1):23-7.

Kastango ES. USP <797>: Making the case for increasing environmental controls in pharmaceutical compounding. 2005.11(4):S1-S12.

Kastango E. USP chapter <797>: The next phase. 2006. 12(4):25-9.

Leone M. Compounding considerations: New alert on exposure to hazardous drugs in the workplace. 2004;10(5):33-36.

Lima HA. Using media fills to evaluate aseptic technique. 1994;1(3):29-33.

NHIA.  New national standards on pharmaceutical compounding. 2004;10(1):20-2.

Rollins CJ. Aluminum content in parenteral products: What clinicians should know about preventing toxicity. 2005:11(1):27-35.

Schloerb PR. Electronic parenteral and enteral nutrition. 2000;6(8):45-7.